Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-3921

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-3921). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Oxcarbazepine 300mg 70518 3921 01)

Oxcarbazepine 300 mg film-coated tablet packaging label showing quantity of 1 tablet. Label includes RX only indication, NDC number 70518-3921-01, manufacturer as Camber Pharma, Inc. in Piscataway, NJ, and repackager RemedyRepack Inc. in Indiana, PA. Storage instructions and a barcode with a 2D QR code are also visible.*

FDA Label Image

Remedy_label (Remedy Label)

Oxcarbazepine 300 mg film-coated tablets, packaged 100 per box. The label is from RemedyRepack Inc. and includes a barcode, NDC 70518-3921-00, storage instructions at 20-25°C with permitted excursions, and advises to see the package insert for directions. Manufacturer: Camber Pharma, Inc.*

FDA Label Image

Oxcarbazepinetabfig1 (Oxcarbazepinetabfig1)

A Kaplan-Meier survival curve chart showing exit rates over time on trial from Day 2 to Day 11. The chart compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The log-rank test p-value 0.0001 is indicated, suggesting a significant difference between the groups.*

FDA Label Image

Oxcarbazepinetabfig2 (Oxcarbazepinetabfig2)

A Kaplan-Meier curve chart showing seizure rate over time (days from first dose to first seizure) comparing Oxcarbazepine treatment group (solid line) and placebo group (dotted line). The graph illustrates seizure-free survival with a log-rank test p-value of 0.046, indicating statistical comparison between groups.*

FDA Label Image

Oxcarbazepinetabfig3 (Oxcarbazepinetabfig3)

A Kaplan-Meier survival curve plotting exit rate over time (days) comparing two treatment groups labeled HIGH (solid line) and LOW (dashed line). The y-axis represents exit rate (0 to 1.0) and the x-axis represents time to exit in days (0 to 130). A log-rank test p-value of 0.0001 is noted in the top left.*

FDA Label Image

Oxcarbazepinetabfig4 (Oxcarbazepinetabfig4)

A Kaplan-Meier survival curve chart depicting exit rate over time (days) for two treatment groups labeled as HIGH and LOW. The X-axis shows time to exit in days (0 to 130) and the Y-axis shows the exit rate (0.0 to 1.0). The LOW group curve rises steeply, reaching near 1.0 exit rate by about 50 days, while the HIGH group curve increases more gradually, remaining below 0.4 exit rate by 130 days. A log-rank test p-value of 0.0001 is indicated on the chart.*

FDA Label Image

Oxcarbazepinetabstruct (Oxcarbazepinetabstruct)

Chemical structure of oxcarbazepine showing a dibenzazepine backbone with keto and amide functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.